DALLAS, Texas, July 21, 2026
Vesalio has announced that its NATURE randomized clinical trial evaluating the enVast™ Coronary Thrombectomy System has been selected for presentation during the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology (ESC) Congress 2026, one of the world’s most influential cardiovascular scientific meetings. The presentation, scheduled for August 29, 2026, in Munich, Germany, highlights the growing clinical significance of the enVast Coronary Thrombectomy System as an adjunctive treatment strategy for ST-segment elevation myocardial infarction (STEMI) patients with large thrombus burden undergoing primary percutaneous coronary intervention (PCI). Selection for the Late-Breaking Clinical Trials session recognizes the scientific importance of the NATURE study and underscores the potential of advanced thrombectomy technologies to improve patient outcomes in acute myocardial infarction, where rapid restoration of coronary blood flow remains essential for reducing mortality and preserving heart function.
NATURE Trial Evaluates Innovative Coronary Thrombectomy Strategy
The NATURE trial is a prospective, multicenter, randomized controlled clinical study designed to evaluate the safety and effectiveness of the enVast™ Coronary Thrombectomy System when used before conventional PCI compared with standard-of-care PCI alone. The study specifically targets STEMI patients presenting with large thrombus burden, a patient population that continues to experience higher procedural complexity and increased risk of adverse cardiovascular events despite advances in interventional cardiology. By removing thrombus before coronary intervention, investigators aim to determine whether the enVast system can improve myocardial reperfusion, reduce procedural complications, and optimize overall clinical outcomes. The selection of the study for the ESC 2026 Late-Breaking Clinical Trials program reflects the importance of generating high-quality randomized evidence for new technologies that may reshape future standards of care in acute coronary syndrome management.
ESC Recognition Highlights Scientific Importance of the Study
The NATURE study will be presented by Professor Marco Valgimigli, MD, of the Cardiocentro Ticino Institute in Lugano, Switzerland, during the ESC scientific session focused on optimizing the management of acute myocardial infarction. The presentation provides international exposure for the investigational technology before a global audience of cardiologists, interventional specialists, researchers, and healthcare professionals. Vesalio’s leadership described the Late-Breaking Clinical Trial selection as a major milestone for both the company and the investigators who contributed to the randomized study. The recognition also reinforces the continued interest in developing innovative reperfusion strategies capable of improving treatment outcomes for patients with complex coronary artery disease, particularly those experiencing acute ST-segment elevation myocardial infarction accompanied by significant thrombus burden.
Advertisement
enVast Platform Expands Advanced Cardiovascular Intervention
The enVast™ Coronary Thrombectomy System forms part of Vesalio’s broader vascular intervention portfolio, which includes the NeVa®, enVast™, and pVasc® technology platforms designed to restore blood flow by removing thromboembolic material from the brain, heart, and peripheral vasculature. According to the company, its technologies have already been used to treat more than 19,000 patients across over 60 countries, demonstrating broad international clinical adoption. As cardiovascular disease remains one of the leading causes of death worldwide, the continued evaluation of innovative thrombectomy devices through rigorous randomized clinical trials such as NATURE is expected to provide valuable evidence supporting future treatment strategies. The upcoming presentation at ESC Congress 2026 may represent an important milestone in advancing catheter-based reperfusion technologies for patients suffering acute myocardial infarction.
Source: Vesalio Press release
